Abstract: The invention is directed a process of preparing a compound of formula (I), wherein R1, R2, R3 and z are as defined herein.

Abstract: The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, R1 and/or R2 as defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain ?-amino carboxamides or ?-amino carboxylic esters. These diphenylazetidinone compounds are useful in the treatment of high blood serum cholesterol levels and the maintenance of the reduced cholesterol levels achieved thereby.

Abstract: The present invention is a process for the preparation of diphenylazetidinone derivatives of the formula (I) or forms thereof comprising the substituents X, R1 and/or R2 as defined herein. More specifically, the invention comprises methods for the preparation of these compounds by cyclization of certain ?-amino carboxamides or ?-amino carboxylic esters. These diphenylazetidinone compounds are useful in the treatment of high blood serum cholesterol levels and the maintenance of the reduced cholesterol levels achieved thereby.

Abstract: The present invention relates to optically active and racemic C.sub.2 -symmetric 2,2'-disubstituted 1,1'-diphosphino-ferrocenes of the formula Ia, to optically active and racemic asymmetric 1',2-disubstituted 1-phosphino-ferrocenes of the formula Ib and to achiral 2,2'-disubstituted 1,1'-diphosphino-ferrocenes of the formula II, to processes for preparing them, especially in accordance with the principle of asymmetric ortho-lithiation, to their use as ligands for transition metal complexes, to transition metal complexes comprising them, and to the use of the transition metal complexes as catalysts, especially in asymmetric syntheses.

Abstract: Compounds of the formula I ##STR1## can be prepared in a multi-day process starting from the compounds of the formulae II and IIIR.sup.1 --SH, II ##STR2## where the substituents R.sup.1, R.sup.2 and R.sup.3 have the meanings given.

Abstract: Compounds of the formula I ##STR1## in which the phenyl rings of the biphenyl molecule can be substituted with up to 8 fluorine and/or chlorine atoms are suitable as catalysts.

Abstract: Crystalline acid addition salts of diastereomerically pure 1-(2,2-dimethylpropionyloxy)ethyl 3-cephem-4-carboxylateThe invention relates to crystalline acid addition salt of the two diastereomers of the 1-(2,2-dimethylpropionyloxy)ethyl 3-cephem-4-carboxylate of the general formula II ##STR1## in which X is the anion of a physiologically acceptable, mono- or polybasic, inorganic or organic acid and the group =N--OH is in the syn-position, pharmaceutical formulations which are active against bacterial infections and contain such cephem derivatives, processes for the preparation of the cephem derivatives and the use of the cephem derivatives for combating bacterial infections.

Abstract: The invention relates to crystalline acid addition salt of the two diastereomers of the 1-(2,2-dimethylpropionyloxy)ethyl 3-cephem-4-carboxylate of the general formula II ##STR1## in which X is the anion of a physiologically acceptable, mono- or polybasic, inorganic or organic acid and the group .dbd.N--OH is in the syn-position, pharmaceutical formulations which are active against bacterial infections and contain such cephem derivatives, processes for the preparation of the cephem derivatives and the use of the cephem derivatives for combating bacterial infections.

Abstract: Process for the diastereoselective reductive pinacol coupling of homochiral .alpha.-aminoaldehydesA process for the preparation of optically pure symmetrical compounds of the formula I ##STR1## is described, in which R.sup.1, R.sup.2 and R.sup.3, are explained in the description, with simultaneous control of the four centers of chirality indicated by *.

Abstract: A novel process is described for preparing tert-butyl (3R, 5S ) 6-hydroxy-3,5-O-isopropylidene-3,5-dihydroxyhexanoate of the formula I ##STR1## which is a valuable structural element for preparing inhibitors of HMG-CoA reductase.